HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MW01-18-150SRM

isoform selective p38alpha MAPK inhibitor

Also Known As:

MW150

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Watterson, D Martin: 2 articles (10/2018 - 01/2017)
2.	Arancio, Ottavio: 1 article (10/2018)
3.	Origlia, Nicola: 1 article (10/2018)
4.	Rutigliano, Grazia: 1 article (10/2018)
5.	Stazi, Martina: 1 article (10/2018)
6.	Bachstetter, Adam D: 1 article (01/2017)
7.	Roy, Saktimayee M: 1 article (01/2017)
8.	Späni, Claudia B: 1 article (01/2017)
9.	Van Eldik, Linda J: 1 article (01/2017)
10.	Zhou, Zhengqiu: 1 article (01/2017)

Related Diseases

1.	Cognitive Dysfunction 01/01/2017 - "The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates. "
2.	Amyloid Plaque 01/01/2017 - "MW150 treatment also increased the IBA1+ microglia within a 15 μm radius of the amyloid plaques, without significantly affecting overall microglia or plaque volume. "
3.	Alzheimer Disease (Alzheimer's Disease) 01/01/2017 - "The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates. "
4.	Neuroinflammatory Diseases 10/01/2018 - "Our findings suggest that the selective inhibition of the stress-activated p38α MAPK with MW150 can attenuate the EC dysfunctions associated with neuroinflammation in an early stage of AD progression."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)